Articles: function.
-
Pulmonary Function TestingSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: According to the predominant phenotype, patients suffering from Chronic Obstructive Pulmonary Oisease (COPO) may present varying and important nutritional profile alterations, up to extreme degrees of severe proteic-energetic malnutrition. In our study, Bioelectricallmpedance Analysis (BIA) has been used in the evaluation of nutritional status (with particular regards to body lean mass alterations) of patients suffering from COPDMETHODS: Up to now, 68 patients (46 M; mean age 70.6 yrs) affected by stable mild to very severe COPD (GOLD 2011 stages l-IV) were evaluated. All of them underwent body plethysmographic evaluation of pulmonary function, six-minute walking test (6MWT) and respiratory muscles strength evaluation (with maximum Inspiratory and expiratory pressures - MIP/MEP - assessment). Moreover, BIA variables were studied with Dietosystem Human Scan, that expresses either quantitative (BIA index) and qualitative (multifrequency relation and phase angle) body lean mass alterations. Furthermore, SIA data from a control age matched group were collected. ⋯ The following authors have nothing to disclose: Francesco De Blasio, Maria Grazia Santaniello, Francesca De Blasio, Giulia Miracco Berlingieri, Barbara Bellofiore, Luca ScalfiNo Product/Research Disclosure Information.
-
ILD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Idiopathic Pulmonary Fibrosis (IPF) is a progressive fatal diffuse parenchymal disease. Pulmonary hypertension (PH) in IPF has been increasingly recognized as a condition with significant prognostic relevance. PH usually develops in patients with advanced IPF however there exists a subset of patients who develop PH at earlier stages. The objective of this study is to compare clinical, functional and radiological parameters in patients with IPF with and without PH at presentation. ⋯ The following authors have nothing to disclose: Margarida Redondo, Diogo Costa, Natalia Melo, Patricia Mota, Antonio MoraisNo Product/Research Disclosure Information.
-
Pulmonary Vascular Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: This patient diagnosed in 2005 with Idiopathic Pulmonary Arterial Hypertension was successfully treated with an ERA for 6 years. In October 2011, functional capacity decreased to IV and the patient was started on IV treprostinil by patient's choice. We achieved a dose of 50 ng-kg-min and patient returned to functional class II. Over time the dose was decreased to 34 ng-kg-min due to intolerable side effects resulting in functional III symptoms and worsening hemodynamics. The patient was given the option to transition to IV epoprostenol which we did on August 7, 2013. ⋯ The following authors have nothing to disclose: Carolyn Pugliese, Raylene Matlock, Ross Davies, Lisa Mielniczuk, George Chandy, Duncan Stewart, Vladimir Contreras-DominguezNo Product/Research Disclosure Information.
-
The use of mechanical circulatory support (MCS) devices has increased sixfold since 2006. Although there is an established legal and ethical consensus that patients have the right to withdraw and withhold life-sustaining interventions when burdens exceed benefits, this consensus arose prior to the widespread use of MCS technology and is not uniformly accepted in these cases. ⋯ Our center recently encountered the challenge of an awake and functionally improving patient with a total artificial heart (TAH) who requested its deactivation. We present a narrative description of this case with discussion of the following questions: (1) Is it ethically permissible to deactivate this particular device, the TAH? (2) Are there any particular factors in this case that are ethical contraindications to proceeding with deactivation? (3) What are the specific processes necessary to ensure a compassionate and respectful deactivation? (4) What proactive practices could have been implemented to lessen the intensity of this case's challenges? We close with a list of recommendations for managing similar cases.
-
Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 12:15 PM - 01:15 PMPURPOSE: Although plasma BNP level is considered to be a useful biomarker for identifying cardiac involvement in patients with Sarcoidosis (Sarc) few data exist for its predictive role in mortality. Our aim was to investigate the predictive role of BNP on all-cause mortality. ⋯ The following authors have nothing to disclose: Elias Gialafos, Vasileios Kouranos, Aggeliki Rapti, Efrosyni Manali, Theodore Papaioannou, Nikolaos Koulouris, Spuridon Papiris, Athol Wells, George TzelepisNo Product/Research Disclosure Information.